In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, highlights FDA’s recent protocol deviations guidance and how it reinforces previous recommendations from industry.
In a recent video interview with Applied Clinical Trials, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, discussed FDA's recent guidance on protocol deviations and its impact on clinical trial management. She highlighted the importance of quality by design (QbD) and critical to quality (CTQ) factors in reducing protocol deviations. Pomerantseva views this guidance as an official acknowledgment of existing practices and an opportunity for improvement.
ACT: How will FDA’s protocol deviations guidance affect the roles of quality by design and critical to quality factors?
Pomerantseva: I do not anticipate any significant impact on the existing roles and responsibilities. To me, themes are that it is consistent with the recommendations provided by TransCelerate, which were followed by many companies already, there's really no significant contradictions. Maybe for those who are behind in terms of the process maturity, there might be some impact, but again, to me it is in line with everything I saw so far, it's also in line with the recently adopted ICH E6(R3) revision. I would rather envision this guidance as an official acknowledgement of what already exists, and with the opportunity maybe to collectively improve and address some of the barriers which we still have. Actually, that is a perfect segue for me, or another important point. This guidance is still a draft and open for comments, I think, until February this year, so I would encourage all the industry peers to provide their feedback, share, and maybe challenge. I provided mine already. I think it's a great opportunity for us to address the challenges we have.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.